Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma

Abroad (travel likely)RecruitingPHASE3

Conditions

Nasopharyngeal Cancinoma (NPC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
Contact: Study coordinator (Liu Guoying) · liugy0109@163.com · 18127919832

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy

Nasopharyngeal Cancinoma (NPC)

Abroad (travel likely)RecruitingPHASE2

Guangzhou, China

Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid

Nasopharyngeal Cancinoma (NPC) · Radiation-induced Oral Mucositis

Abroad (travel likely)RecruitingPHASE3

Beijing, China · Fuzhou, China

Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.

Nasopharyngeal Cancinoma (NPC)

Abroad (travel likely)RecruitingPHASE3

Dongguan, China · Guangzhou, China

Phase 3 Trial Comparing IMRT or IMPT Plus CIRT for Patients With NPC

Nasopharyngeal Cancinoma (NPC)

Abroad (travel likely)RecruitingPHASE3

Shanghai, China